Steinhilb Michelle L, Dias-Santagata Dora, Mulkearns Erin E, Shulman Joshua M, Biernat Jacek, Mandelkow Eva-Maria, Feany Mel B
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Neurosci Res. 2007 May 1;85(6):1271-8. doi: 10.1002/jnr.21232.
The microtubule-associated protein tau is hyperphosphorylated abnormally in AD and related neurodegenerative disorders. Many phospho epitopes created by proline directed kinases (SP/TP sites) show relative specificity for disease states. To test whether phosphorylation at the disease-associated SP/TP sites affects tau toxicity in vivo, we expressed a form of tau in Drosophila in which all SP/TP sites are mutated to alanine. We find that blocking phosphorylation at SP/TP motifs markedly reduces tau toxicity in vivo. Using phosphorylation-specific antibodies, we identify a positive correlation between increased phosphorylation at disease-associated sites and neurotoxicity. We use the phosphorylation-incompetent version of tau to show that kinase and phosphatase modifiers of tau neurotoxicity, including cdk5/p35, the JNK kinase hemipterous and PP2A act via SP/TP phosphorylation sites. We provide direct evidence in an animal model system to support the role of phosphorylation at SP/TP sites in playing a critical role in tau neurotoxicity.
微管相关蛋白tau在阿尔茨海默病(AD)及相关神经退行性疾病中会异常过度磷酸化。许多由脯氨酸定向激酶产生的磷酸化表位(丝氨酸/苏氨酸位点)对疾病状态具有相对特异性。为了测试疾病相关丝氨酸/苏氨酸位点的磷酸化是否会影响tau在体内的毒性,我们在果蝇中表达了一种所有丝氨酸/苏氨酸位点均突变为丙氨酸的tau形式。我们发现,阻断丝氨酸/苏氨酸基序处的磷酸化可显著降低tau在体内的毒性。使用磷酸化特异性抗体,我们确定疾病相关位点磷酸化增加与神经毒性之间存在正相关。我们使用无磷酸化能力的tau版本来表明,tau神经毒性的激酶和磷酸酶调节剂,包括细胞周期蛋白依赖性激酶5/周期蛋白p35、JNK激酶半翅目和蛋白磷酸酶2A(PP2A),是通过丝氨酸/苏氨酸磷酸化位点起作用的。我们在动物模型系统中提供了直接证据,以支持丝氨酸/苏氨酸位点的磷酸化在tau神经毒性中起关键作用。